Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes
Publication date: Available online 28 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Zachary L. Quinn, Karam Zakharia, Janet L. Schmid, John J. Schmieg, Hana Safah, Nakhle S. SabaAbstractPrimary dural diffuse large B-cell lymphoma (PD-DLBCL) is a rare and aggressive B-cell non-Hodgkin lymphoma (NHL) that can present in intracranial or intraspinal locations. While the optimal management is unknown, PD-DLBCL therapy is often mirrored after primary central nervous system lymphoma (PCNSL) therapy and aggressive treatment with a high dose Methotrexate (MTX)-based regimen is frequently used. Our comprehensive, retrospective study of 24 reported cases of PD-DLBCL provide the most complete analysis of this rare disease including data on biology, treatment outcomes and survival. Our findings demonstrate good outcomes following induction treatment with R-CHOP, suggesting that these cases can be treated as DLBCL rather than PCNSL, obviating the need for more aggressive and toxic approaches. The durable responses following R-CHOP also confirm that PD-DLBCL is not protected by the blood brain barrier. Data in this paper were presented in part at the 2017 American Society of Hematology Annual Meeting, abstract # 4166.
Authors: Lee JY, Kim HJ, Kwon E, Choi JY, Oh HJ, Kim JS PMID: 33029984 [PubMed]
Publication date: Available online 10 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Zena Chahine, John Lister, Rodney E. Wegner, Santhosh Sadashiv
Authors: Morimoto A, Fujioka Y, Ushiku T, Kurokawa M PMID: 33028779 [PubMed - as supplied by publisher]
Authors: Li H, Zhang J, Chen Y PMID: 33034436 [PubMed - as supplied by publisher]
CONCLUSIONS: Hence, it is important to work with patients and their families to identify and strengthen adaptive and coping behaviors. That is possible only through the synergistic working of a multidisciplinary team made up of experienced doctors, psychologists, and social workers while in contact with patient Associations. PMID: 33034432 [PubMed - as supplied by publisher]
We report the rare case of a patient co-existing NS and DLBCL. DLBCL might be pathogenesis of NS; the findings are supported by the presence of MN, an underlying malignancy (DLBCL), and the lack of anti-PLA2R antibodies. Although further investigation is warranted, our case suggests that DLBCL is a possible cause of secondary MN. PMID: 33028760 [PubMed - in process]
In conclusion, our multidisciplinary approach to prevent de novo hepatitis B is considered useful. PMID: 33028756 [PubMed - in process]
Authors: Cáceres-Perkins W, Cabanillas F, San Vicente G, Rivera-Franceschini C, Sobrino-Najul E, Vega-Vázquez LI, Conde-Sterling D Abstract Mucosa-associated lymphoid tissue (MALT) lymphomas are B-cell neoplasms that commonly affect the gastrointestinal (GI) tract, usually the stomach. In most cases, extranodal marginal zone lymphoma (ENMZL) is an indolent disease. Bone marrow involvement is common with MALT lymphoma accompanied by paraproteinemia; such involvement impels disease progression. Here, we present the case of an 82-year-old Hispanic patient with long-standing ENMZL in whom the gastric site...
CONCLUSION: Our data suggest that these two polymorphisms do not contribute to AD in the population from the Mersin region of the Eastern Mediterranean. Further studies with larger sample sizes must be conducted to ascertain the association between the 2 polymorphisms. PMID: 33031695 [PubMed - as supplied by publisher]
AbstractA vast majority of oral cancer patients in developing countries present in an advanced stage with borderline resectable/inoperable stage to busy resource-constrained tertiary cancer centers. Conventional chemotherapy protocols are associated with issues like toxicity, tolerance, cost, and compliance. The present study was conducted to assess the feasibility of low-cost home-based chemotherapy options. Single-arm feasibility study was done in borderline resectable/inoperable oral cancer patients. Home-based oral neoadjuvant chemotherapy consisting of oral methotrexate 15 mg/m2 once a week and oral celecoxib 20...